Pang-Dian Fan

6PUBLICATIONS
40CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.

Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su

|Dec 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.

Tony Mok, Pasi A Jänne, Makoto Nishio

|Sep 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

Helena A Yu, Yasushi Goto, Hidetoshi Hayashi

|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.

Helena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi

|Aug 11, 2022
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.

Hiroki Sato, Daisuke Kubota, Huan Qiao

|Jun 08, 2018
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Pang-Dian Fan, Giuseppe Narzisi, Anitha D Jayaprakash

Pageof 1

Frequent Collaborators

4 joint publications

Pasi A Jänne

3 joint publications

Helena A Yu

3 joint publications

Hidetoshi Hayashi

2 joint publications

Dong-Wan Kim